GRAILGRAL -0.44%12 EBITDA Margin % is -332.88% as of Mar. 2026. GuruFocus rates GRAL with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, GRAIL ranks worse than 86.76% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. GRAIL's EBITDA for the
three
months ended in Mar. 2026 was $-135.8 Mil. GRAIL's Revenue for the
three
months ended in Mar. 2026 was $40.8 Mil. Therefore, GRAIL's EBITDA margin for the quarter that ended in Mar. 2026 was -332.88%.
GRAIL (NAS:GRAL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
GRAIL EBITDA Margin % Related Terms
GRAIL EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for GRAIL's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRAL vs VCYT, ADPT, TWST: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, GRAIL's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GRAIL EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, GRAIL's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where GRAIL's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GRAIL (GRAL) has a EBITDA Margin % of -332.88% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GRAIL and its competitors. According to the industry distribution chart, GRAIL ranks #177 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 86.8%.
Is GRAIL's EBITDA Margin % too high?
GRAIL's current EBITDA Margin % is -332.88%. Based on the distribution chart, GRAIL ranks #177 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, GRAIL has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does GRAIL's EBITDA Margin % compare to VCYT and ADPT?
According to the Medical Diagnostics & Research industry distribution chart, GRAIL ranks #177 out of 204 companies for EBITDA Margin %. This places GRAIL in the lower half of its industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on GRAIL and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GRAIL's current EBITDA Margin % is -332.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRAIL stock overvalued right now?
GRAIL (GRAL) has a current EBITDA Margin % of -332.88%. The current EBITDA Margin % is -332.88%. GRAIL's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For GRAIL (GRAL), the current EBITDA Margin % is -332.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
12GF Score
Get the complete analysis for GRAL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GRAL has been successfully added to your 
